Alternative Data for Coeptis Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 26 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,026 | Sign up | Sign up | Sign up |
| X Followers | 514 | Sign up | Sign up | Sign up |
| X Mentions | 4 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 5 | Sign up | Sign up | Sign up |
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer.
| Price | $13.65 |
| Target Price | Sign up |
| Volume | 85,980 |
| Market Cap | $68M |
| Year Range | $7.05 - $18.8 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Coeptis Therapeutics S-4 declared effective by SECJanuary 6 - Thefly.com |
Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z SquaredJanuary 6 - GlobeNewswire |
|
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates BFIN, COEP, ARIS, CIO on Behalf of ShareholdersOctober 7 - GlobeNewswire |
|
 |
Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 5% – Time to Sell?August 29 - ETF Daily News |
 |
Coeptis Therapeutic Holdings Details $835M Transaction Structure with Z-Squared; Vanderbilt Report Publishes CoverageJanuary 5 - Yahoo |
Clinical Stage Partnering Terms and Agreements in Pharma and Biotech: 1,775 Deals + SEC Contracts, Top 25 Dealmaker Profiles, 2020-2025October 13 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 240,000 | 45,000 | 190,000 | -160,000 | -2.5M | |
| Q2 '25 | 200,000 | 45,000 | 160,000 | -3.5M | -4M | -1.170 |
| Q1 '25 | 63,000 | 45,000 | 18,000 | -3.1M | -3M | -0.950 |
| Q4 '24 | 1.9M | 260,000 | -260,000 | -3M | -2.7M | -1.423 |
| Q3 '24 | 0 | 430,000 | -430,000 | -1.8M | -1.5M | -1.080 |
Insider Transactions View All
| DeSilva Tara filed to buy 30,466 shares at $0.6. January 16 '24 |
| DeSilva Tara filed to buy 32,266 shares at $0.6. January 16 '24 |
| Cogley Brian filed to buy 30,000 shares at $0.7. January 17 '24 |
| Mehalick David filed to buy 2,768,611 shares at $0.7. January 9 '24 |
| Mehalick David filed to buy 2,782,615 shares at $0.7. January 9 '24 |
Similar companies
Read more about Coeptis Therapeutics (COEP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Coeptis Therapeutics
The Market Cap of Coeptis Therapeutics is $68M.
Currently, the price of one share of Coeptis Therapeutics stock is $13.65.
The COEP stock price chart above provides a comprehensive visual representation of Coeptis Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Coeptis Therapeutics shares. Our platform offers an up-to-date COEP stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Coeptis Therapeutics (COEP) does not offer dividends to its shareholders. Investors interested in Coeptis Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Coeptis Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
